Development of Human Anthrax Immune Globulin

NIH RePORTER · NIH · N01 · $749,260 · view on reporter.nih.gov ↗

Abstract

The Development of the Human Anthrax Immune Globulin (AIGIV) contract supports studies to assess the efficacy of anthrax immune globulin for intravenous use (AIGIV) as a therapeutic for anthrax disease.

Key facts

NIH application ID: 10428337
Project number: 272200700034C-P00006-9999-1
Recipient: EMERGENT PRODUCT DEVELOPMENT GAITHERSBUR
Principal Investigator: HOPKINS ROBERT
Activity code: N01
Funding institute: NIH
Fiscal year: 2021
Award amount: $749,260
Award type: —
Project period: 2007-09-28 → 2011-12-31